Your browser version may not work well with NCBI's Web applications. More information here...
1: N Engl J Med. 2005 Dec 22;353(25):2667-72.Click here to read Links
Comment in:
N Engl J Med. 2005 Dec 22;353(25):2633-6.
N Engl J Med. 2006 Mar 30;354(13):1423-4; author reply 1423-4.

Oseltamivir resistance during treatment of influenza A (H5N1) infection.

de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J.

Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. mddejong@hcm.vnn.vn

Influenza A (H5N1) virus with an amino acid substitution in neuraminidase conferring high-level resistance to oseltamivir was isolated from two of eight Vietnamese patients during oseltamivir treatment. Both patients died of influenza A (H5N1) virus infection, despite early initiation of treatment in one patient. Surviving patients had rapid declines in the viral load to undetectable levels during treatment. These observations suggest that resistance can emerge during the currently recommended regimen of oseltamivir therapy and may be associated with clinical deterioration and that the strategy for the treatment of influenza A (H5N1) virus infection should include additional antiviral agents. Copyright 2005 Massachusetts Medical Society.

PMID: 16371632 [PubMed - indexed for MEDLINE]

Related Articles

Patient Drug Information
  • Oseltamivir (Tamiflu®) Oseltamivir is used to treat some types of influenza infection ('flu') in adults and children (older than 1 year of age) who have had symptoms of the flu for no longer than 2 days. This medication is also used to prevent...
    » read more ...